9. S. Partula, A. de Guerra, J. S. Fellah, J. Charlemagne, *J. Immunol.* **157**, 207 (1996).
10. D. L. DiGiusto and E. Palmer, *Mol. Immunol.* **31**, 693 (1994).
11. The α wild-type, β wild-type, αIII, and βIII constructs have been previously described (8). The α wild-type amino acid sequence from the interchain Cys to the COOH-terminus is CDATLTEKS**FETDMNLN**FQNLSVM-GLRILLLKVAGFNLLMTLRLWSS (30), with the α-CPM indicated in bold. The β wild-type amino acid sequence from the interchain Cys to the COOH-terminus is CGITSASYQQGVLSATILYEILLGKATLYAVLVSTLVVMAM VKRKNS. Similarly, the corresponding αIII amino acid sequence is CDATLTEKS**FET** V TVHTEKVNMMSLTVLGL-RLLFAKTIAINFLLTVKLFF. The underlined sequences are derived from murine Cδ and consequently, the distal five amino acids (DMNLN) of the α-CPM have been replaced. To permit surface expression of this chimeric α-chain, the αIII construct was paired with the βIII cDNA (8), which encodes the corresponding amino acid sequence CGITSASYQQGVLSATILYLLLLLKSVIYLAIISFSL-LRRTSVCGNEKKS. The underlined sequences are derived from murine Cγ1. Although this TCR is encoded by chimeric α and β chains, the functional defects associated with the αIII/βIII TCR are due to the absence of an intact α-CPM (8). cDNAs were excised with Eco RI and Bam and individually cloned into the Sal I and Bam sites of the expression vector pHSE3′ (31).
12. B. Hausmann and E. Palmer, data not shown.
13. P. Borgulya, H. Kishi, Y. Uematsu, H. von Boehmer, *Cell* **69**, 529 (1992).
14. In contrast to irradiated B6 mice, irradiated B6 athymic nude mice reconstituted with T cell–depleted bone marrow from α-CPM mutant animals failed to generate significant numbers of transgenic T cells. Therefore, the appearance of mutant T cells in the periphery is dependent on the presence of a thymus (12).
15. H. Suzuki, J. A. Punt, L. G. Granger, A. Singer, *Immunity* **2**, 413 (1995).
16. W. Swat, L. Ignatowicz, H. von Boehmer, P. Kisielow, *Nature* **351**, 150 (1991).
17. J. A. Punt, B. A. Osborne, Y. Takahama, S. O. Sharrow, A. Singer, *J. Exp. Med.* **179**, 709 (1994).
18. D. M. Page, L. P. Kane, J. P. Allison, S. M. Hedrick, *J. Immunol.* **151**, 1868 (1993).
19. S. J. Curnow, M. Barad, N. Brun-Roubereau, A. M. Schmitt-Verhulst, *Cytometry* **16**, 41 (1994).
20. B. T. Bäckström and E. Palmer, unpublished observations.
21. V. P. Dave *et al.*, *EMBO J.* **16**, 1360 (1997).
22. M. Cohn and R. Langman, *Behring Inst. Mitt.* **70**, 219 (1982).
23. K. A. Swan *et al.*, *EMBO J.* **14**, 276 (1995).
24. J. Alberola-Ila, K. A. Hogquist, K. A. Swan, M. J. Bevan, R. M. Perlmutter, *J. Exp. Med.* **184**, 9 (1996).
25. C. C. O'Shea, T. Crompton, I. R. Rosewell, A. C. Hayday, M. J. Owen, *Eur. J. Immunol.* **26**, 2350 (1996).
26. R. Amakawa *et al.*, *Cell* **84**, 551 (1996).
27. I. Correa *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* **89**, 653 (1992).
28. M. Bigby *et al.*, *J. Immunol.* **151**, 4465 (1993).
29. E. Schweighoffer and B. J. Fowlkes, *J. Exp. Med.* **183**, 2033 (1996).
30. Single-letter abbreviations for the amino acid residues are as follows: A, Ala; C, Cys; D, Asp; E, Glu; F, Phe; G, Gly; H, His; I, Ile; K, Lys; L, Leu; M, Met; N, Asn; P, Pro; Q, Gln; R, Arg; S, Ser; T, Thr; V, Val; W, Trp; and Y, Tyr.
31. H. Pircher *et al.*, *EMBO J.* **8**, 719 (1989).
32. M. M. Rozdzial, R. T. Kubo, S. L. Turner, T. H. Finkel, *J. Immunol.* **153**, 1563 (1994).
33. T. Shiohara *et al.*, *ibid.* **138**, 1979 (1987).
34. The monoclonal antibodies (mAbs) to Vα2.1 (B20.1), Vβ8 (MR5-2), CD3ε (145-2c11), CD4 (H129.19), and CD8 (53-6.7) were purchased from PharMingen (San Diego, CA). The ζ chain mAb H146-968 (32) and the I-Abm12 mAb 3JP (33) were purified from culture supernatants using protein G Sepharose beads (Pharmacia). Cells were analyzed on a FACScan or a FAC-Star Plus (Becton Dickinson) using the CellQuest software (Becton Dickinson).
35. B. T. Bäckström, B. Rubin, A. Peter, G. Tiefenthaler, E. Palmer, *Eur. J. Immunol.* **27**, 1433 (1997).
36. The stimulation of DP thymocytes and Hoechst

staining to detect apoptotic cells was carried out as previously described (16–19). Briefly, stimulator splenocytes were prepared from B6 (I-Ab) or B6.C.H-2-bm12 (I-Abm12) mice. We cultured 2×10^6 stimulators (in 2 ml) for 12 to 16 hours in the presence or absence of titrated amounts of the I-Abm12 blocking mAb 3JP (34) in 24-well plates with 1×10^6 thymocytes from B6.Rag-2−/− mice expressing the wild-type or the α-CPM mutant TCR. Cells were then harvested and stained with Hoechst 33342 (1 μg/ml) followed by staining with CD4 mAb, CD8 mAb, and propidium iodide (2.5 μg/ml) and analyzed by flow cytometry.
37. We thank A. Peter and S. Stotz for generating the αIII and βIII constructs; J. Bluestone, L. Bolliger, R. Langman,

DARPP-32: Regulator of the Efficacy of Dopaminergic Neurotransmission

A. A. Fienberg,* N. Hiroi,† P. G. Mermelstein, W.-J. Song, G. L. Snyder, A. Nishi, A. Cheramy, J. P. O'Callaghan, D. B. Miller, D. G. Cole,‡ R. Corbett, C. N. Haile, D. C. Cooper, S. P. Onn, A. A. Grace, C. C. Ouimet, F. J. White, S. E. Hyman,§ D. J. Surmeier,‖ J.-A. Girault, E. J. Nestler, P. Greengard

Dopaminergic neurons exert a major modulatory effect on the forebrain. Dopamine and adenosine 3′,5′-monophosphate–regulated phosphoprotein (32 kilodaltons) (DARPP-32), which is enriched in all neurons that receive a dopaminergic input, is converted in response to dopamine into a potent protein phosphatase inhibitor. Mice generated to contain a targeted disruption of the DARPP-32 gene showed profound deficits in their molecular, electrophysiological, and behavioral responses to dopamine, drugs of abuse, and antipsychotic medication. The results show that DARPP-32 plays a central role in regulating the efficacy of dopaminergic neurotransmission.

Midbrain dopaminergic neurons play a critical role in multiple brain functions (1–3). Abnormal signaling through dopaminergic pathways has been implicated in several major neurological and psychiatric disorders, including Parkinsonism, schizophrenia, and drug abuse (4). The physiological and clinical importance of dopamine pathways in the brain makes it imperative to elucidate the mechanisms by which dopamine, acting on its receptors, produces its biological effects on target neurons.

One well-studied molecular target for the actions of dopamine is DARPP-32 (5), which is highly enriched in virtually all medium spiny neurons in the striatum (6). Dopamine, acting on D1-like receptors, causes activation of protein kinase A (PKA) and phosphorylation of DARPP-32 on threonine-34 (7). Conversely, dopamine, acting on D2-like receptors, through both inhibition of PKA and activation of calcium/calmodulin–dependent protein phosphatase (protein phosphatase 2B/calcineurin), causes the dephosphorylation of DARPP-32 (8). Several other neurotransmitters that interact with the dopamine system also stimulate either phosphorylation or dephosphorylation of DARPP-32 through vari-

ous direct and indirect mechanisms (9). DARPP-32, in its phosphorylated but not its dephosphorylated form, acts as a potent inhibitor of protein phosphatase-1 (PP-1) (10). PP-1 controls the state of phosphorylation and the physiological activity of a wide array of neuronal phosphoproteins, including neurotransmitter receptors, ion channels, ion pumps, and transcription factors (11).

That numerous pathways regulate, or are regulated by, the DARPP-32/PP-1 signaling cascade suggests the central importance of DARPP-32 in mediating the biological effects of dopamine. To evaluate this hypothesis, given the absence of any specific pharmacological antagonists for DARPP-32, we generated mice that lack this protein (12). The absence of DARPP-32 protein from mice homozygous for the mutated DARPP-32 gene was demonstrated by immunoblotting striatal extracts. Immunocytochemistry confirmed that the DARPP-32 protein was absent from mutant mouse brain (13), although the brains of the DARPP-32 mutant mice appeared normal structurally (14, 15).

Phosphorylated DARPP-32 inhibits dephosphorylation of numerous other proteins by PP-1. Therefore, we examined the possi-

bility that the DARPP-32 mutant mice might show an aberrant state of phosphorylation of PP-1 substrates in response to stimulation by dopamine. One protein phosphorylated in striatum and nucleus accumbens in response to dopamine is the NR1 subunit of the *N*-methyl-D-aspartate (NMDA)–type glutamate receptor (*16*). We tested the effect of mutation of the DARPP-32 gene on dopamine-stimulated phosphorylation of this receptor (Fig. 1A). The total amount of NR1 in slices of nucleus accumbens was unaffected by the loss of DARPP-32. Dopamine increased NR1 phosphorylation by three- to fourfold in wild-type mice, but this increase was abolished in DARPP-32 mutant mice (*17*). The demonstration that DARPP-32 is involved in dopamine-regulated phosphorylation of the NR1 receptor is consistent with recent electrophysiological studies. Thus, in rat and mouse striatal neurons, dopamine, D1 agonists, and forskolin enhanced responses mediated by activation of NMDA receptors (*18, 19*). In *Xenopus* oocytes, DARPP-32 was found to be a critical component of adenosine 3′,5′-monophosphate–dependent regulation of NMDA current (*20*).

Activation of the dopamine D1 receptor–PKA–DARPP-32 cascade alters the electrophysiological properties of dopaminoceptive neurons in several ways. One target of D1 receptors in striatal neurons is the electrogen-

ic ion pump Na$^+$- and K$^+$-dependent adenosine triphosphatase (Na$^+$,K$^+$-ATPase) (*21*), which regulates membrane potential and electrical excitability. The principal role of this transmembrane protein in neurons is to

maintain the Na$^+$ and K$^+$ concentration gradients and the membrane potential that underlie electrical excitability. The activity of Na$^+$,K$^+$-ATPase in dissociated mouse striatal neurons was reduced by the D1 receptor

A. A. Fienberg, G. L. Snyder, A. Nishi, P. Greengard, Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York, NY 10021, USA. N. Hiroi, C. N. Haile, E. J. Nestler, Laboratory of Molecular Psychiatry, Yale University School of Medicine and Connecticut Mental Health Center, New Haven, CT 06508, USA. P. G. Mermelstein, W.-J. Song, D. J. Surmeier, Department of Anatomy and Neurobiology, College of Medicine, University of Tennessee, Memphis, TN 38163, USA. A. Cheramy and J. A. Girault, INSERM U114, College de France, 75005 Paris, France. J. P. O'Callaghan and D. B. Miller, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, Morgantown, WV 26505, USA. D. G. Cole and S. E. Hyman, Molecular and Developmental Neuroscience and Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA. R. Corbett, Hoechst Marion Roussel, Inc., Somerville, NJ 08807, USA. D. C. Cooper and F. J. White, Department of Neuroscience, Chicago Medical School, North Chicago, IL 60064, USA. S. P. Onn and A. A. Grace, Department of Neuroscience, University of Pittsburgh, Pittsburgh, PA 15260, USA. C. C. Ouimet, Program in Neuroscience, Florida State University, Tallahassee, FL 32306, USA.

*To whom correspondence should be addressed. E-mail: fienba@rockvax.rockefeller.edu

†Present address: Laboratory of Molecular Psychobiology, Departments of Psychiatry and Neuroscience, Albert Einstein College of Medicine, Bronx, NY 10461, USA.

‡Present address: Vertex Pharmaceuticals, Cambridge, MA 02139, USA.

§Present address: Office of the Director, National Institute of Mental Health, Bethesda, MD 20892, USA.

∥Present address: Department of Physiology, NUIN, Northwestern University School of Medicine, Chicago, IL 60611, USA.

Fig. 1. Reduced ability of dopaminergic agonists to regulate electrophysiological properties of dopaminoceptive neurons from DARPP-32 mutant mice. (**A**) Effect of dopamine (100 μM) on phosphorylation of NR1 subunit of glutamate NMDA receptor in nucleus accumbens slices. Data are expressed as percent radioactivity for the zero time controls (mean ± SEM, *n* = 5, *P* < 0.05, Student's *t* test). (**B**) Na$^+$,K$^+$-ATPase activity. Acutely dissociated striatal neurons prepared from wild-type or mutant mice were incubated in the absence or presence of the D1 receptor agonist SKF 82526 (1 μM) for 10 min (*n* = 5). Na$^+$,K$^+$-ATPase activity was assayed as described (*21*). Basal Na$^+$,K$^+$-ATPase activity was similar in wild-type (442 ± 27 nmol of inorganic phosphate per milligram of protein per minute) and mutant (394 ± 56 nmol of inorganic phosphate per milligram of protein per minute) mice. *P* < 0.01; paired *t* test, compared with control. (**C**) (a and c) Plot of peak calcium current versus time in striatal neurons. Application of the D1 receptor agonist SKF 81297 (5 μM) resulted in greater inhibition of the whole-cell current in wild-type neurons (21.4% ± 2.4%, mean ± SEM, *n* = 10) than in mutant neurons (15% ± 1.1%, *n* = 12, *P* < 0.05, Mann-Whitney *U* test). (Inset) Box-plot summary of the D1 receptor–mediated inhibition of calcium currents in wild-type and mutant neurons. (b and d) Representative current traces from the records used to construct (a) and (c), respectively. (**D**) Inhibitory efficacy of the D1 receptor agonist SKF 81297 (0.01 M, pipette concentration) on firing rate of nucleus accumbens neurons tested in vivo. Glutamate (0.01 M, pipette concentration) was used to drive the activity of nucleus accumbens neurons. For SKF 81297 delivered at lower ionotophoretic currents, glutamate-driven activity was significantly less in neurons recorded from wild-type (*n* = 7), but not in those from mutant (*n* = 14) mice. Each data point represents mean ± SEM. *P* < 0.05, **P* < 0.01, analysis of variance (ANOVA) followed by Dunnett's test.

agonist SKF 82526 (Fig. 1B). This inhibition was abolished by the D1 receptor antagonist SCH 23390 (22). In neurons from DARPP-32 mutant mice, the ability of the D1 agonist to inhibit Na^+,K^+-ATPase was eliminated (Fig. 1B).

D1 receptor stimulation also reduces the responsiveness of medium spiny neurons in the striatum to excitatory input at hyperpolarized membrane potentials through mechanisms that are independent of Na^+,K^+-ATPase activity (23, 24). Two such mechanisms involve PKA-mediated changes in the properties of voltage-dependent ion channels—notably, Na^+ and Ca^{2+} channels (18, 25). For example, N- and P/Q-type Ca^{2+} currents are reduced by D1 receptor–mediated activation of PKA in medium spiny neurons of rats (26). Whole-cell voltage clamp recordings of Ca^{2+} currents revealed that D1 receptor stimulation produces a similar, potent modulation in acutely isolated striatal neurons from wild-type mice (Fig. 1C). Although basal current densities were unchanged, the modulation of Ca^{2+} currents by D1 receptor agonists was reduced by about

50% in striatal neurons from DARPP-32 mutant mice (Fig. 1C).

Intracellular recordings from medium spiny neurons in slices also provided evidence for an attenuation of D1 receptor–mediated changes in cellular excitability in DARPP-32 mutant mice. In current-clamp recordings from medium spiny neurons of rats at hyperpolarized membrane potentials, D1 receptor stimulation increased rheobase current (current injection threshold to elicit a single spike) through PKA-mediated reduction in Na^+ currents (24, 25). In wild-type mice D1 receptor agonists also produced an increase in the current injection threshold of medium spiny neurons. This effect was significantly decreased in neurons from the DARPP-32 mutant mice (27).

D1 receptor stimulation also reduces the responsiveness of medium spiny neurons to exogenous glutamate in vivo (18, 28). In the present experiments, extracellular electrodes were used to record from type 1 medium spiny neurons in the nucleus accumbens. Glutamate and a dopaminergic ligand were applied near the recorded cell by iontophore-

sis. In wild-type mice, iontophoretic application of a D1 agonist produced a dose-dependent decrease in glutamate-evoked activity (Fig. 1D). In mutant mice, this D1 receptor–mediated inhibition was significantly attenuated. Thus, all the electrophysiological results show that D1 receptor–triggered, PKA-dependent suppression of medium spiny neuron excitability at hyperpolarized membrane potentials was significantly attenuated in DARPP-32 mutant mice.

The psychostimulant D-amphetamine induces a massive outflow of dopamine from nigrostriatal nerve terminals, which in turn increases the release of γ-aminobutyric acid (GABA) from nerve terminals of medium spiny neurons of rat in vivo and in vitro (29). This paradigm was used to assess the ability of endogenous dopamine to stimulate the efflux of [³H]GABA in striatal slices from wild-type and DARPP-32 mutant mice. A large efflux of [³H]GABA was evoked by D-amphetamine in wild-type mice, but this effect was significantly attenuated in the DARPP-32 mutant mice (Fig. 2A). This effect of the DARPP-32 deletion was attributable to both a decrease in amphetamine-induced dopamine release, as shown in striatal slices (Fig. 2B) and synaptosomes (Fig. 2C), and a decrease in dopamine-induced GABA release (Fig. 2D). Further evidence for an alteration in the properties of dopaminergic neurons in DARPP-32 mutant mice was obtained in studies of methamphetamine neurotoxicity (30). The administration of a neurotoxic regimen of methamphetamine to wild-type mice caused severe damage to dopaminergic nerve terminals, as shown by a reduction in dopamine (Fig. 2E) and an increase in glial fibrillary acidic protein (GFAP), an index of injury-induced gliosis (Fig. 2F). These effects were abolished in the mutant mice (Fig. 2, E and F). The observations that deletion of the DARPP-32 gene reduced amphetamine-induced dopamine re-

Fig. 2. (A to D) Reduced ability of amphetamine (4×10^{-7} M) and dopamine (10^{-5} M) to induce neurotransmitter release in DARPP-32 mutant mice. [³H]GABA release (A and D) and [³H]dopamine release (B and C) were measured in striatal microdiscs (A, B, and D) or synaptosomes (C) from wild-type (■, ▲) and mutant (○) mice treated with drug (■, ○) or vehicle (▲). Drugs were applied for 5 min as indicated by solid bars (37). In no case was there a significant difference between wild-type and mutant mice, either in accumulation of radiolabeled neurotransmitter or in basal amounts of neurotransmitter outflow (vehicle data are shown only for wild-type mice). Data were obtained from 8 to 16 independent samples for each treatment. ANOVA was followed by Newman-Keuls test, *$P < 0.01$. (E and F): Loss of ability of a neurotoxic regimen of methamphetamine to damage dopaminergic nerve terminals in DARPP-32 mutant mice. Damage was assessed by loss of dopamine (E) and induction of GFAP (F). Homogenates of striatum were prepared from wild-type and mutant mice killed 72 hours after the last of four subcutaneous doses of methamphetamine (10 mg/kg in isotonic saline, open bars) or vehicle (solid bars) administered at 2-hour intervals. Each value represents the mean ± SEM for five mice. *Significantly different from wild type, $P < 0.05$ (ANOVA followed by Duncan's test).


Table 1. Reduced ability of raclopride to induce catalepsy in DARPP-32 mutant mice. Catalepsy testing (39) was conducted 30 min after intraperitoneal injection of vehicle or raclopride ($n = 12$ per dose group). Wild-type and mutant control mice injected with vehicle remained stationary for an average of 17 s. Data represent percentage increase in catalepsy (mean ± SEM) relative to vehicle-injected control animals. Data were analyzed by ANOVA, followed by Student's t test.

Raclopride (mg/kg)	Increase in catalepsy (%)	
	Wild type	Mutant
0.25	236.5 ± 48.7	35.0 ± 31.5**
0.5	369.5 ± 62.2	65.7 ± 33.5**
1.0	579.2 ± 65.2	387.9 ± 43.3*
2.0	865.6 ± 49.2	806.1 ± 48.7

*$P < 0.05$ compared with wild-type control; **$P < 0.01$ compared with wild-type control.

lease from, and methamphetamine-induced toxicity to, dopaminergic neurons demonstrate that the effect of this deletion on the biological properties of the medium spiny neurons is strong enough to alter the characteristics of other neurons in this brain region, which do not contain DARPP-32.

Fig. 3. Reduced ability of psychostimulant drugs of abuse to induce molecular and behavioral responses in DARPP-32 mutant mice. (**A**) Quantitation of Fos-like immunoreactive striatal nuclei in wild-type (solid bars, $n = 4$) and mutant (open bars, $n = 7$) mice given amphetamine (10 mg/kg) intraperitoneally 2 hours before use (38). Counts were obtained from digitized images of sections through the anterior and posterior striatum divided into quadrants along the dorsal-ventral and medial-lateral axes. *$P < 0.05$ compared with wild-type control (Mann-Whitney U test). (**B**) Induction of ΔFosB isoforms in mouse striatum by chronic intraperitoneal administration of cocaine (20 mg/kg once a day for 6 days). (Left) Immunoblotting with antiserum to Fos-like protein (33), showing the 35- to 37-kD ΔFosB isoforms and a 45-kD protein (representing full-length FosB). (Right) Quantitative analysis of induction of the ΔFosB isoforms; $n = 8$ to 15, *$P < 0.01$ compared with the saline control [Fisher least significant difference (LSD) post hoc tests]. (**C**) Locomotor activity (33), induced by a single, acute cocaine injection (10 or 20 mg/kg) in wild-type (left) and mutant (right) mice; *$P < 0.05$, **$P < 0.01$ compared with the respective control (Fisher LSD post hoc tests, $n = 6$ to 15).

A well-characterized molecular consequence of dopaminergic signaling in the striatum is the regulation of gene expression. Agents that increase dopaminergic neurotransmission—for example, amphetamine and cocaine—have been shown to induce several Fos-like proteins in medium spiny neurons in the striatum, an effect that is mediated largely by activation of D1-like receptors (31). Acute exposure to amphetamine elicited a robust induction of Fos-like immunoreactivity throughout the striatum of wild-type mice. Significant reductions in this response were observed in most regions of the striatum in DARPP-32 mutant mice (Fig. 3A). This deficit in c-Fos induction in the mutant mice was partially overcome by administration of a higher dose of amphetamine (32). Chronic exposure to drugs of abuse leads to the accumulation of distinct Fos-like proteins, isoforms of ΔFosB (33), an effect that also is largely mediated by D1-like receptors (34). Induction of the 35- to 37-kD ΔFosB isoforms, observed in striatum of wild-type mice in response to chronic administration of cocaine, was virtually abolished in the DARPP-32 mutant mice (Fig. 3B). These results indicate that DARPP-32 plays an important role in the short- and long-term changes in gene expression elicited by acute and chronic drug exposure, respectively.

Acute exposure to cocaine stimulates locomotor activity in rodents, an effect largely mediated by increased dopaminergic transmission in the striatum, particularly the nucleus accumbens [see (1)]. This effect of cocaine, which is mediated in part via the dopamine D1 receptors (35), was significantly attenuated in DARPP-32 mutant mice at lower, but not higher doses of the drug (Fig. 3C). Acute locomotor responses to D-amphetamine were also reduced in the mutant mice (36). No difference, however, was observed between wild-type and mutant mice in baseline measures of locomotor activity (Fig. 3C) or in the spontaneous locomotor activity measured by 24-hour monitoring in the animals' home cages (36).

Raclopride and other antipsychotic drugs induce catalepsy in rodents by a mechanism involving blockade of striatal D2-like dopamine receptors. Because raclopride increases the basal phosphorylation of DARPP-32 and prevents the D2 receptor–mediated decrease in DARPP-32 phosphorylation in mouse striatal slices (8), we tested the possibility that this behavioral effect of raclopride might be altered in the DARPP-32 mutant mice. Raclopride produced catalepsy in both wild-type and mutant mice; however, its effectiveness at lower concentrations (0.25 and 0.5 mg/kg) was greatly reduced in the mutant mice (Table 1).

This study has revealed that inactivation of the DARPP-32 gene markedly reduced,

and in some cases abolished, various responses to dopaminergic agonists and antagonists. In some instances, the impairment of responses could be overcome by increasing the concentration of the test substance used. These observations can be readily explained by the fact that stimulation of dopamine receptors regulates phosphorylation of key substrates by two synergistic pathways: one involves direct phosphorylation of these substrates by PKA, and the other involves inhibition of their dephosphorylation by PP-1, the activity of which is regulated by DARPP-32. Both pathways are required when the levels of stimulation of dopamine receptors are low (most physiological situations). In contrast, at supraphysiological levels of stimulation, the robust activation of the direct PKA pathway alone appears sufficient to restore responses in the mutant mice, which is why some of the deficits observed in these mice could be overcome by increasing the strength of the stimuli. From these data we conclude that a cascade involving dopamine-mediated receptor activation of DARPP-32, inhibition of PP-1, and potentiation of phosphorylation of neuronal substrates plays a major role in regulating the efficacy of dopaminergic neurotransmission under physiological conditions.

Numerous neurotransmitters besides dopamine have been shown to produce physiological responses and to regulate phosphorylation or dephosphorylation of DARPP-32 in medium spiny neurons (9). The results of this study indicate that such regulation of DARPP-32 is probably a major molecular mechanism by which information received through dopaminergic and other signaling pathways is integrated in these neurons, which constitute the principal efferent pathway from the striatum. Furthermore, the decreased sensitivity of mutant mice to drugs of abuse and antipsychotic agents indicates the involvement of DARPP-32 in mediating the pharmacological effects of both of these classes of compounds. Drugs that mimic or block the inhibitory effects of DARPP-32 on PP-1 might provide useful agents for the treatment of Parkinson's disease, schizophrenia, drug addiction, and other neuropsychiatric disorders involving abnormal dopaminergic function.

References and Notes

1. P. W. Kalivas and J. Stewart, *Brain Res. Rev.* **16**, 223 (1991).
2. G. F. Koob, *Trends Pharmacol. Sci.* **13**, 177 (1992); E. J. Nestler and G. K. Aghajanian, *Science* **278**, 58 (1997).
3. G. V. Williams and P. S. Goldman-Rakic, *Nature* **376**, 572 (1995).
4. R. L. Albin, A. Young, J. B. Penney, *Trends Neurosci.* **12**, 366 (1989); M. B. Knable and D. R. Weinberger, *J. Psychopharmacol.* **11**, 123 (1997); G. F. Koob and M. Le Moal, *Science* **278**, 52 (1997).
5. S. I. Walaas, D. W. Aswad, P. Greengard, *Nature* **301**, 69 (1983); S. I. Walaas, A. C. Nairn, P. Greengard, *J. Neurosci.* **3**, 302 (1983).
6. C. C. Ouimet, P. E. Miller, H. C. Hemmings Jr., S. I. Walaas, P. Greengard, *J. Neurosci.* **4**, 114 (1984); C. C.

Ouimet and P. Greengard, *J. Neurocytol.* **19**, 39 (1990); K. C. Langley, C. Bergson, P. Greengard, C. C. Ouimet, *Neuroscience* **78**, 977 (1997).

7. H. C. Hemmings Jr., K. R. Williams, W. H. Konigsberg, P. Greengard, *J. Biol. Chem.* **259**, 14486 (1984).

8. A. Nishi *et al.*, *J. Neurosci.* **17**, 8147 (1997).

9. P. Greengard *et al.*, *Brain Res. Rev.* **26**, 274 (1998).

10. H. C. Hemmings Jr., P. Greengard, H. Y. Tung, P. Cohen, *Nature* **310**, 503 (1984).

11. S. Shenolikar and A. C. Nairn, *Adv. Sec. Messenger Phosphoprotein Res.* **23**, 1 (1991).

12. Disruption of the DARPP-32 gene was accomplished in the E14 embryonic stem cell line (129/Ola-derived substrain) by using a targeting vector containing 2.2 kb (5′) and 6.0 kb (3′) of genomic DNA flanking a neomycin-resistance gene (*PGK-neo*). Homologous recombination at the endogenous locus was designed to result in the replacement of a 400–base pair genomic DNA fragment containing the start of translation with *PGK-neo*. The choice of targeted clones was based on the shift of a genomic fragment from 6.2 to 7.6 kb as determined by Southern (DNA) blot analysis. After C57BL/6J blastocyst injection and embryo transfer, chimeric offspring were crossed to C57BL/6J females, and those mice carrying the mutation were crossed to generate heterozygous and homozygous mutants. Mice used in this study were selected from the offspring of heterozygous × heterozygous breeding pairs. Mice were selected from three colonies that were maintained at the F_1, N_2, and N_6 levels of backcrossing. Backcrossing was carried out into the C57BL/6 inbred mouse strain (from The Jackson Laboratory). None of the phenotypes presented appeared to be influenced by the level of backcrossing. All the mice used were males, except for the methamphetamine toxicity experiments, in which females were used. All mice were 3 to 6 months of age, except when we examined the electrophysiology of calcium channels in ~3- to 5-week-old mice. DARPP-32 mutant mice showed no obvious differences from wild-type mice in measures of overall health such as weight and food intake. Matings of heterozygotes yielded wild-type, heterozygote, and mutant genotypes in Mendelian proportions and with equal percentages of males and females.

13. C. C. Ouimet, unpublished observations.

14. The size and gross morphological appearance of the brains of the mutant mice were normal. In addition, the densities of neurons, nerve terminals, and dendritic spines in the striatum were indistinguishable from those of wild-type controls (*13*). We used immunocytochemistry to examine major subsets of striatal neurons in these mice. Calbindin, a marker for the striatal matrix compartment [C. R. Gerfen, *Trends Neurosci.* **15**, 133 (1992); A. M. Graybiel, *ibid.* **13**, 244 (1990)], showed a normal pattern of distribution. Met-enkephalin, a marker for the striatal indirect pathway, also showed apparently normal immunoreactivity in the striatum and in its projection areas, the globus pallidus–ventral pallidum, in mutant mice. Dynorphin, a marker for the striatonigral direct pathway, showed no apparent abnormality in the striatum or in the terminals of these neurons in ventral midbrain (substantia nigra and ventral tegmental area). Taken together, our findings indicate that if any defects occur during the development of the striatum they are subtle and unlikely to be responsible for the distinct phenotype in adult mutant mice reported here.

15. Striatal levels of D1-like and D2-like receptor binding as well as D1-like stimulated adenylyl cyclase were equivalent in wild-type and mutant mice (P. Svenningsson, B. Fredholm, J.-A. Girault, unpublished observations).

16. G. Snyder, A. Fienberg, I. Dulubova, A. C. Nairn, P. Greengard, *Soc. Neurosci. Abstr.* **22**, 380 (1996).

17. Mouse nucleus accumbens slices from wild-type and DARPP-32 mutant mice, prelabeled with [^{32}P]orthophosphoric acid (2 mCi per slice), were incubated in the presence of dopamine (100 μM) and the dopamine-uptake inhibitor nomifensine (10 μM) for 2.5 or 5 min. The NMDA-NR1 subunit was immunoprecipitated [G. Fisone *et al.*, *J. Biol. Chem.* **270**, 2427 (1995)] and ^{32}P incorporation was quantitated by PhosphorImager analysis (Molecular Dynamics).

18. C. Cepeda, N. A. Buchwald, M. S. Levine, *Proc. Natl. Acad. Sci. U.S.A.* **90**, 9576 (1993).

19. C. S. Colwell and M. S. Levine, *J. Neurosci.* **15**, 1704 (1995); M. S. Levine *et al.*, *ibid.* **16**, 5870 (1996).

20. T. Blank *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* **94**, 14859 (1997).

21. A. M. Bertorello, J. F. Hopfield, A. Aperia, P. Greengard, *Nature* **347**, 386 (1990).

22. A. Nishi, unpublished observations.

23. N. Uchimura, H. Higashi, S. Nishi, *Brain Res.* **375**, 368 (1986); A. Akaike, Y. Ohno, M. Sasa, S. Takaori, *ibid.* **418**, 262 (1987).

24. P. Calabresi, N. Mercuri, P. Stanzione, A. Stefani, G. Bernardi, *Neuroscience* **20**, 757 (1987).

25. D. J. Surmeier, J. Eberwine, C. J. Wilson, A. Stefani, S. T. Kitai, *Proc. Natl. Acad. Sci. U.S.A.* **89**, 10178 (1992); S. N. Schiffman, P.-M. Lledo, J.-D. Vincent, *J. Physiol. (London)* **483**, 95 (1994).

26. D. J. Surmeier, J. Bargas, H. C. Hemmings Jr., A. C. Nairn, P. Greengard, *Neuron* **14**, 385 (1995).

27. S.-P. Onn and A. A. Grace, unpublished observations.

28. S. R. White, G. C. Harris, K. M. Imel, M. J. Wheaton, *Brain Res.* **681**, 167 (1995).

29. J.-A. Girault, U. Spampinato, J. Glowinski, M. Besson, *Neuroscience* **19**, 1109 (1986); B. Floran, J. Aceves, A. Sierra, D. Martinez-Fong, *Neurosci. Lett.* **116**, 136 (1990).

30. J. P. O'Callaghan and D. B. Miller, *J. Pharmacol. Exp. Ther.* **270**, 741 (1994).

31. A. M. Graybiel, R. Mortalla, H. A. Robertson, *Proc. Natl. Acad. Sci. U.S.A.* **87**, 6912 (1990); S. T. Young, L. J. Porrino, M. J. Iadarola, *ibid.* **88**, 1291 (1991).

32. D. G. Cole, unpublished observations.

33. N. Hiroi *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* **94**, 10397 (1997).

34. B. T. Hope *et al.*, *Neuron* **13**, 1235 (1994); H. E. Nye, B. T. Hope, M. B. Kelz, M. J. Iadarola, E. J. Nestler, *J. Pharmacol. Exp. Ther.* **275**, 1671 (1995).

35. M. Xu *et al.*, *Cell* **79**, 945 (1994).

36. R. Corbett, unpublished observations.

37. Neurotransmitter outflow from striatal microdiscs and synaptosomes was measured as described [T. Galli *et al.*, *Neuroscience* **50**, 769 (1992)].

38. C. Konradi, R. L. Cole, K. Heckers, S. E. Hyman, *J. Neurosci.* **14**, 5623 (1994).

39. R. G. Pertwee, *Br. J. Pharmacol.* **46**, 753 (1972).

40. Supported by the A.P.D.A. (A.A.F.), U.S. Public Health Service grants MH40899 and DA10044 (P.G.), DA 08227 and DA 07359 (E.J.N.), and a grant from Ministère de l'Education Nationale, de l'Enseignement Superieur et de la Recherche (97H0003; J.-A.G.). We thank E. J. Robertson, A. Furley, A. Plump, and S. Tonegawa for valuable help in the initial phases of this work. We thank P. Ingrassia, E. Griggs, F. Artaud, and M. Lhirondel for excellent assistance.